Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

30.65
+0.80002.68%
Post-market: 30.650.00000.00%16:10 EDT
Volume:247.88K
Turnover:7.58M
Market Cap:1.47B
PE:-10.04
High:31.20
Open:29.73
Low:29.50
Close:29.85
52wk High:52.93
52wk Low:23.75
Shares:47.98M
Float Shares:32.38M
Volume Ratio:0.98
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:3.48
PE(LYR):-10.70

Loading ...

Goldman Sachs Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jul 22

Analysts Offer Insights on NA Companies: Solv Energy (Nasdaq: MWH), Rapport Therapeutics, Inc. (RAPP) and Volvo Car AB Class B (OtherVLVOF)

TIPRANKS
·
Jul 18

Rapport Therapeutics Price Target Maintained with a $65.00/share by BTIG

Dow Jones
·
Jul 16

Rapport Therapeutics CEO Abraham Ceesay Sells 8,210 Common Shares Worth $328,018

Reuters
·
Jul 16

Rapport Therapeutics management to meet with Citizens

TIPRANKS
·
Jul 16

4x P B For Rapport Therapeutics (RAPP) After Russell Index Additions Looks Pricey

Simply Wall St.
·
Jul 06

Rapport Therapeutics CEO Abraham Ceesay Disposes of Common Shares Worth $327,031.55

Reuters
·
Jul 02

Does Truist’s New RAPP Coverage Subtly Reframe Rapport Therapeutics’ Long-Term Credibility Story (RAPP)?

Simply Wall St.
·
Jun 26

1 Reason Rapport Therapeutics (RAPP) Looks Pricey Following Truist Buy Coverage

Simply Wall St.
·
Jun 25

Rapport Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 25

Leerink Partners Initiates Rapport Therapeutics at Outperform With $52 Price Target

MT Newswires Live
·
Jun 24

Rapport Therapeutics initiated with an Outperform at Leerink

TIPRANKS
·
Jun 24

Rapport Therapeutics Inc : Leerink Partners Initiates Coverage with Outperform Rating; Price Target $52

THOMSON REUTERS
·
Jun 24

Rapport Therapeutics Holds 2026 Annual Shareholder Meeting

TIPRANKS
·
Jun 11

Rapport Therapeutics shareholders elected Class II directors at annual meeting

Reuters
·
Jun 11

Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

TIPRANKS
·
Jun 05

BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Jun 02

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08

Reuters
·
May 29

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG

TIPRANKS
·
May 21